March 05, 2026   |   Read Online

Morning View: (CTXR) Just Hit Our Early Watchlist—Here’s Why 

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Market Maven Insights Just Put (Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) On Today’s Watchlist—Thursday, March 5, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Pull Up (CTXR) While It’s Still Early…

March 5, 2026
Morning View | (CTXR) Just Hit Our Early Watchlist—Here’s Why 

Dear Reader,

In biotech, the biggest shift often happens when a company moves beyond development and successfully brings an approved therapy to market. 

Many firms spend years advancing clinical programs, but only a small number ultimately reach the point where a commercial launch begins producing real sales. 

One company that recently crossed that milestone is Citius Pharmaceuticals, Inc. (Nasdaq: CTXR). 

The company recently reported its first product revenue following a year-end launch, marking an important step after years focused primarily on clinical development. At the same time, (CTXR)continues advancing a pipeline targeting large medical markets with significant unmet need, while expanding its presence in oncology through its newly commercialized asset. 

Because of that shift toward commercialization alongside ongoing pipeline progress, (CTXR) is moving to the top of our watchlist today—Thursday, March 5, 2026.

(CTXR)’s share structure adds additional context to the setup. (CTXR) reports fewer than 22M shares available to the public, creating a relatively tight float for a company entering the commercial stage. Despite recent developments, the company continues to trend below $1, placing it under many traditional screening thresholds. 

From an analyst perspective, Jason Kolbert of D. Boral Capital recently reiterated a $6 target, representing more than 600% upside potential above the recent $0.80 range. 

That outlook reflects the firm’s view of the company’s oncology platform ownership along with the potential of late-stage programs continuing through regulatory pathways.

With commercialization now underway and additional programs advancing, (CTXR) appears to be entering a new phase of its development cycle. 

Advancing a Multi-Program Biopharma Platform

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)is a late-stage biopharmaceutical company focused on bringing specialized therapies to patients across oncology, infectious disease, and critical care markets. 

The company’s development strategy centers on proprietary, first-in-class treatment candidatesdesigned to address areas where existing therapies remain limited or where meaningful treatment gaps still exist. 

A key part of this strategy is its oncology subsidiary, in which Citius maintains approximately a 74.8% ownership stake. The subsidiary reached an important milestone in December 2025 with the launch of LYMPHIR, a targeted immunotherapy developed for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). 

Alongside its oncology program, the company continues to advance additional late-stage assets. These include Mino-Lok, a therapy designed to treat catheter-related bloodstream infections, and Halo-Lido, a topical treatmentcandidate being developed for hemorrhoids. 

With a newly launched oncology therapy and multiple programs continuing through late-stage development, (CTXR) is positioning itself within specialized healthcare segments where unmet medical need remains significant. 

Early Commercial Rollout Taking Shape

A key development for (CTXR) heading into 2026 is the rollout of its newly launched oncology therapy. 

In February 2026, the company reported roughly $3.9M generated from initial sales tied to the December 2025 launch, representing the first commercial activity associated with the product. 

Early uptake indicates initial interest from physicians treating CTCL, an important early step as the therapy begins establishing its presence within the oncology community. 

According to the company’s oncology subsidiary, the estimated U.S. addressable market for the therapy exceeds $400M, providing  meaningful potential as awareness and utilization potentially expand. 

Beyond the early sales figures, the launch also reflects an operational milestone, highlighting the company’s ability to bring a complex biologic therapy through development and into commercial distribution while continuing to advance additional programs in its pipeline. 

Multiple Programs Moving Through the Pipeline

While LYMPHIR and Mino-Lok represent the most advanced programs today, Halo-Lido is another component of (CTXR)’s broader development portfolio. 

Halo-Lido is being developed to address hemorrhoid-related symptoms, a condition affecting a large patient population. More than 10M people in the United States report symptoms, yet there are currently no FDA-approved prescription treatments that combine both a corticosteroid and an anesthetic. 

The company completed a Phase 2b study in 2023 and is now working with the FDA to determine the potential pathway toward a Phase 3 clinical trial. 

Looking ahead, (CTXR)’s near-term priorities include continuing to expand the LYMPHIR rollout through its oncology subsidiary, advancing Mino-Lok through the remaining NDA process with the FDA, and preparing Halo-Lido for potential late-stage development. 

Across these programs, the company is targeting oncology, infectious disease, and outpatient treatment segments, creating several parallel interests as the pipeline continues to progress. 

Experienced Leadership and Evolving Market Position

As (CTXR) moves into 2026, the company is progressing from a primarily development-stage focus toward a structure that includes commercial activity alongside continued pipeline advancement. In its fiscal 2025 reporting, management highlighted efforts to maintain a disciplined operating model while directing capital toward its most advanced programs. 

The company is led by an experienced pharmaceutical team. Chairman and CEO Leonard Mazur has decades of industry experience and has been involved in building and exiting multiple healthcare companies. Vice Chairman Myron Holubiak, the former President of Roche Laboratories, brings significant experience in large-scale pharmaceutical operations and commercialization. 

(CTXR) is also operating within healthcare segments where demand for new treatment approaches remains strong. In oncology, there has been a growing shift toward targeted immunotherapies, a category where LYMPHIRis positioned for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). 

In critical care, the company’s Mino-Lok program is designed to address catheter-related bloodstream infections by attempting to salvage infected central venous catheters rather than requiring removal. (CTXR) estimates this at more than $2B globally, including over $1B in the United States. 

7 Reasons (CTXR) Is On Our Early Watchlist — Thursday, March 5, 2026

1. Small Float: Fewer than 22M shares in the public float, creating a relatively limited share supply.
2. Analyst Coverage: D. Boral Capital reiterated a $6 target, suggesting 600%+ upside potential above the recent $0.80 range.
3. Commercial Launch: LYMPHIR launched in December 2025, marking the company’s move into the commercial stage.
4. Early Sales Activity: (CTXR) reported $3.9M from initial LYMPHIR salesfollowing the launch.
5. Late-Stage Results: A leading pipeline program met primary and secondary endpoints in a pivotal Phase 3 study.
6. Large Market Potential: Targeting a $400M CTCL market and catheter infection markets exceeding $2B globally.
7. Pipeline Progress: With commercialization underway, additional programs continue advancing toward regulatory and late-stage milestones. 

Pull Up (CTXR) While It’s Still Early…

Several developments are beginning to bring (CTXR) onto more screens. 

(CTXR) recently reached a key operational milestone with the December 2025 launch of LYMPHIR, marking its entry into the commercial stage after years of development. 

Structurally, the setup is also notable. Fewer than 22M shares are listed as available to the public, creating a relatively tight float, while D. Boral Capital has reiterated a $6 analyst target. The company has also reported positive Phase 3 results from its Mino-Lok program, with additional pipeline work continuing around Halo-Lido. 

Beyond individual programs, (CTXR) is operating in healthcare segments with meaningful demand, including a CTCL market estimated around $400M and catheter-related infection markets exceeding $2B globally. 

With commercialization underway and several pipeline programs continuing to advance, (CTXR) is one we’ll be watching closely this morning.

Pull up (CTXR) while it’s still early.  

Also, keep a lookout for our next update, it could be coming shortly after the bell. 

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com (“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 03/04/2026 and ending on 03/05/2026 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC eight thousand seven hundred fifty USD (“Funds”). To date, including under the previously described agreement, Source Coastal Media LLC has been paid eighteen thousand seven hundred fifty USD (“Funds”). These Funds were part of the fifty five thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (CTXR:US).}

^{Please see important disclosure information here: https://marketmaveninsights.com/disclosure/ctxr-C7PxT/#details}

Update your email preferences or unsubscribe here

© 2026 Market Maven Insights 

1691 Forum Place Ste B #332
West Palm Beach, Florida 33401, United StatesTerms of Service